Loading publications…
The last 5 uploaded publications
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
C. Owen, Xue Bai, Gaik Tin Quah, Serigne Lo, Clara Allayous, Sophia Callaghan, Clara Martínez-Vila, Roslyn Wallace, Prachi Bhave, Irene L. M. Reijers, Nicola Thompson, Vito Vanella, Camille L. Gérard, Sandrine Aspeslagh, Alice Labianca, Adnan Khattak, Mario Mandalà, Wen Xu, Bart Neyns, Olivier Michielin, Christian U. Blank, Sarah J. Welsh, Andrew Haydon, Shahneen Sandhu, Joanna Mangana, Jennifer L. McQuade, Paolo A. Ascierto, Lisa Zimmer, Douglas B. Johnson, Ana Arance, Paul Lorigan, Célèste Lebbé, Matteo S. Carlino, Ryan J. Sullivan, Georgina V. Long, Alexander M. Menzies (2021). Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. , 32(7), DOI: https://doi.org/10.1016/j.annonc.2021.03.204.
Article62 days agoIpilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers, Alison M. Weppler, Allison Betof Warner, James R. Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Khang Nguyen, Lisa Zimmer, Claudia Trojaniello, Dan Stout, Megan Lyle, Oliver Klein, Camille L. Gérard, Olivier Michielin, Andrew Haydon, Paolo A. Ascierto, Matteo S. Carlino, Célèste Lebbé, Paul Lorigan, Douglas B. Johnson, Shahneen Sandhu, Serigne Lo, Christian U. Blank, Alexander M. Menzies, Georgina V. Long (2021). Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. , 22(6), DOI: https://doi.org/10.1016/s1470-2045(21)00097-8.
Article62 days agoDelayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
C. Owen, Xue Bai, Gaik Tin Quah, Serigne Lo, Clara Allayous, Sophia Callaghan, Clara Martínez-Vila, Roslyn Wallace, Prachi Bhave, Irene L. M. Reijers, Nicola Thompson, Vito Vanella, Camille L. Gérard, Sandrine Aspeslagh, Alice Labianca, Adnan Khattak, Mario Mandalà, Wen Xu, Bart Neyns, Olivier Michielin, Christian U. Blank, Sarah J. Welsh, Andrew Haydon, Shahneen Sandhu, Joanna Mangana, Jennifer L. McQuade, Paolo A. Ascierto, Lisa Zimmer, Douglas B. Johnson, Ana Arance, Paul Lorigan, Célèste Lebbé, Matteo S. Carlino, Ryan J. Sullivan, Georgina V. Long, Alexander M. Menzies (2021). Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. , 32(7), DOI: https://doi.org/10.1016/j.annonc.2021.03.204.
Article62 days agoIpilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers, Alison M. Weppler, Allison Betof Warner, James R. Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Khang Nguyen, Lisa Zimmer, Claudia Trojaniello, Dan Stout, Megan Lyle, Oliver Klein, Camille L. Gérard, Olivier Michielin, Andrew Haydon, Paolo A. Ascierto, Matteo S. Carlino, Célèste Lebbé, Paul Lorigan, Douglas B. Johnson, Shahneen Sandhu, Serigne Lo, Christian U. Blank, Alexander M. Menzies, Georgina V. Long (2021). Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. , 22(6), DOI: https://doi.org/10.1016/s1470-2045(21)00097-8.
Article62 days agoIpilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply
Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers, Allison Betof Warner, James R. Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Lisa Zimmer, Claudia Trojaniello, Oliver Klein, Camille L. Gérard, Olivier Michielin, Andrew Haydon, Paolo A. Ascierto, Matteo S. Carlino, Célèste Lebbé, Paul Lorigan, Douglas B. Johnson, Shahneen Sandhu, Serigne Lo, Alexander M. Menzies, Georgina V. Long (2021). Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. , 22(8), DOI: https://doi.org/10.1016/s1470-2045(21)00419-8.
Letter62 days ago